View in EDS

P-123 Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting.

Saved in:
Bibliographic Details
Title: P-123 Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting.
Authors: Lago, N. Martínez1, Lopez, B. Carnero2, Gomez, J. De la Cámara3, Vázquez-Rivera, F.4, Montes, A. Fernández5, Dios, N. de6, Maseda, A. Carral2, Augusto, M. Pellón3, Folgar, S. Candamio7, Reboredo-Lopez, M.8, Fernandez, M. Salgado9, Martin, E. Gallardo10, Covela-Rúa, M.2, Suarez, B. Graña8, Campos, M. Carmona2, Vázquez, E. Brozos7, Rendo, C. Reboredo8, Aldana, G. Quintero2, Ventura, C. Grande6, Ínsua, Y. Vidal7
Source: Annals of Oncology. 2020 Supplement 3, Vol. 31, pS130-S130. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.04.205